Management of cirrhosis due to chronic hepatitis C

Journal of Hepatology

Volumn 42, Issue SUPPL. 1, 2005, Pages

  Everson, Gregory T ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; CREATININE; HEMOGLOBIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANEMIA; ASCITES FLUID; BONE MARROW SUPPRESSION; CANCER SCREENING; CHRONIC HEPATITIS; CLINICAL EXAMINATION; CREATININE CLEARANCE; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; GENERAL CONDITION DETERIORATION; HEMOGLOBIN DETERMINATION; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; INFECTION RISK; KIDNEY FUNCTION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION; MEDICAL ASSESSMENT; MONOTHERAPY; NEUTROPENIA; PATIENT MONITORING; PRIORITY JOURNAL; RELAPSE; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; THROMBOCYTOPENIA; VIRUS LOAD;

EID: 14944369827     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2005.01.009     Document Type: Review

References (53)

1. World Health Organization. Weekly epidemiological record, 1999; 74:421-428.
2. M.J. Alter, D. Kruszon-Moran, O.V. Nainan, G.M. McQuillan, F. Gao, and L.A. Moyer The prevalence of hepatitis C infection in the United States, 1988 through 1994 N Engl J Med 341 1999 556 562
3. G.L. Armstrong, M.J. Alter, G.M. McQuillan, and H.S. Margolis The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States Hepatology 31 2000 777 782
4. E. Kenny-Walsh Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish hepatology research group N Engl J Med 340 1999 1228 1233
5. M. Wiese, F. Berr, M. Lafrenz, H. Porst, and U. Oesen Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study Hepatology 32 2000 91 96
6. L.B. Seeff, Z. Buskell-Bales, E.C. Wright, S.J. Durako, H.J. Alter, and F.L. Iber Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group N Engl J Med 327 1992 1906 1911
7. L.B. Seeff Natural history of hepatitis C Am J Med 107 1999 10S 15S
8. A.J. Rodger, S. Roberts, A. Lanigan, S. Bowden, T. Brown, and N. Crofts Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975 Hepatology 32 2000 582 587
9. M.J. Tong, N.S. el-Farra, A.R. Reikes, and R.L. Co Clinical outcomes after transfusion-associated hepatitis C N Engl J Med 332 1995 1463 1466
10. K. Kiyosawa, T. Sodeyama, E. Tanaka, Y. Gibo, K. Yoshizawa, and Y. Nakano Interrelationship of blood transfusion non-A, non-B hepatitis and hepatocellular carcinoma. Analysis by detection of antibody to hepatitis C virus Hepatology 12 1990 671 675
11. K. Kiyosawa, T. Umemura, T. Ichijo, A. Matsumoto, K. Yoshizawa, and A. Gad Hepatocellular carcinoma: recent trends in Japan Gastroenterology 127 2004 S17 S26
12. G. Fattovich, G. Giustina, F. Degos, F. Tremolada, G. Diodati, and P. Almasio Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients Gastroenterology 112 1997 463 472
13. L. Serfaty, H. Aumaitre, O. Chazouilleres, A.M. Bonnand, O. Rosmorduc, and R.E. Poupon Determinants of outcome of compensated hepatitis C virus-related cirrhosis Hepatology 27 1998 1435 1440
14. K.Q. Hu, and M.J. Tong The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States Hepatology 29 1999 1311 1316
15. M.H. Khan, G.C. Farrell, K. Byth, R. Lin, M. Weltman, and J. George Which patients with hepatitis C develop liver complications? Hepatology 31 2000 513 520
16. W.M. Lee, J.L. Dienstag, K.L. Lindsay, A.S. Lok, H.L. Bonkovsky, and M.L. Shiffman Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders Control Clin Trials 25 2004 472 492
17. G.L. Davis, L.A. Balart, E.R. Schiff, K. Lindsay, H.C. Bodenheimer, and R.P. Perrillo Treatment of chronic hepatitis C, with recombinant interferon alfa. A multicenter randomized, controlled trial N Engl J Med 321 1989 1501 1506
18. A.M. Di Bisceglie, P. Martin, C. Kassianides, M. Lisker-Melman, L. Murray, and J. Waggoner Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial N Engl J Med 321 1989 1506 1510
19. J.H. Hoofnagle, and A.M. Di Bisceglie The treatment of chronic viral hepatitis N Engl J Med 336 1997 347 356
20. J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, and V.K. Rustgi Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N Engl J Med 339 1998 1485 1492
21. G.L. Davis, R. Esteban-Mur, V. Rustgi, J. Hoefs, S.C. Gordon, and C. Trepo Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C N Engl J Med 339 1998 1493 1499
22. M.W. Fried, M.L. Shiffman, R.K. Reddy, C. Smith, G. Marino, and F. Goncales Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection N Engl J Med 347 2002 975 982
23. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M.L. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial Lancet 358 2001 958 965
24. S.J. Hadziyannis, H. Sette, T.R. Morgan, V. Balan, M. Diago, and P. Marcellin Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
25. E.J. Heathcote, M.L. Shiffman, W.G. Cooksley, G.M. Dusheiko, S.S. Lee, and L. Balart Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis N Engl J Med 343 2000 1673 1680
26. M.L. Shiffman Retreatment of patients with chronic hepatitis C Hepatology 36 2002 S128 S134
27. F. Ahmed, and I.M. Jacobson Treatment of relapsers after combination therapy for chronic hepatitis C Gastroenterol Clin North Am 33 2004 513 526
28. S. Zeuzem Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 140 2004 370 381
29. G. Saracco, A. Olivero, A. Ciancio, S. Carenzi, A. Smedile, and G. Cariti A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy Hepatology 36 2002 959 966
30. S.J. Cheng, P.A. Bonis, J. Lau, N.Q. Pham, and J.B. Wong Inteferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials Hepatology 33 2001 231 240
31. K.J. Cummings, S.M. Lee, E.S. West, J. Cid-Ruzafa, S.G. Fein, and Y. Aoki Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials JAMA 285 2001 193 199
32. M.L. Shiffman, A.M. Di Bisceglie, K.L. Lindsay, C. Morishima, E.C. Wright, and G.T. Everson Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment Gastroenterology 126 2004 1015 1023
33. G.T. Everson, J.C. Hoefs, P. Malet, and for the HALT-C Trial Group Impaired virologic response in patients with advanced liver disease due to chronic hepatitis C is independently linked to severity of disease: results from the HALT-C trial Hepatology 40 2004 180A
34. P.S. Kamath, R.H. Wiesner, M. Malinchoc, W. Kremers, T.M. Therneau, and C.L. Kosberg A model to predict survival in patients with end-stage liver disease Hepatology 33 2001 464 470
35. R.H. Wiesner, S.V. McDiarmid, P.S. Kamath, E.B. Edwards, M. Malinchoc, and W.K. Kremers Application of survival models to liver allocation Liver Transpl 7 2001 567 580
36. R.H. Wiesner, M. Sorrell, and F. Villamil International liver transplantation society expert panel. Report of the first international liver transplantation society expert panel consensus conference on liver transplantation and hepatitis C Liver Transpl 9 2003 S1 S9
37. D.B. Strader, T. Wright, D.L. Thomas, and L.B. Seeff AASLD practice guideline: diagnosis, management, and treatment of hepatitis C Hepatology 39 2004 1147 1171
38. G.T. Everson Long-term outcome of patients with chronic hepatitis C and decompensated liver disease treated with the LADR protocol [low-accelerating- dose-regimen] Hepatology 36 2002 297A
39. G.T. Everson Treatment of patients with hepatitis C virus on the waiting list Liver Transpl 9 2003 S90 S94
40. X.G.-R.M. Forns, T. Serrano, A. Feliu, F. Suarez, de la Mat, and J.C. Garcia-Valdecasas Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation J Hepatol 39 2003 389 396
41. R.M.B.J. Thomas, G. Guzman-Hartman, S. Yong, P. Cavaliere, and D.H. Van Thiel Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation Liver Transpl 9 2003 905 915
42. J.S. Crippin, T. McCashland, N. Terrault, P. Sheiner, and M.R. Charlton A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation Liver Transpl 8 2002 350 355
43. E.J. Heathcote Treatment considerations in patients with hepatitis C and cirrhosis J Clin Gastroenterol 37 2003 395 398
44. R.J. Fontana, G.T. Everson, S. Tuteja, H.E. Vargas, and M.L. Shiffman Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis Clin Gastroenterol Hepatol 2 2004 183 197
45. D.T. Dietrich, R. Wasserman, N. Brau, T.I. Hassanein, E.J. Bini, and P.J. Bowers Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa Am J Gastroenterol 98 2003 2491 2499
46. M.L. Shiffman, C.M. Hofmann, E.B. Thompson, A. Ferreira-Gonzalez, M.J. Contos, and A. Koshy Relationship between biochemical, virological and histological response during interferon treatment of chronic hepatitis C Hepatology 26 1997 780 785
47. T. Poynard, J. McHutchison, M. Manns, C. Trepo, K. Lindsay, and Z. Goodman Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 2002 1303 1313
48. C. Camma, D. Di Bona, F. Schepis, E.J. Heathcote, S. Zeuzem, and P.J. Pockros Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data Hepatology 39 2004 333 342
49. H. Yoshida, Y. Shiratori, M. Moriyama, Y. Arakawa, T. Ide, and M. Sata Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan: IHIT study group - inhibition of hepatocarcinogenesis by interferon therapy Ann Intern Med 131 1999 174 181
50. M.L. Shiffman, C.M. Hofmann, M.J. Contos, V.A. Luketic, A.J. Sanyal, and R.K. Sterling A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia Gastroenterology 117 1999 1164 1172
51. L. Alric, M. Duffaut, J. Selves, K. Sandre, M. Mularczyck, and J. Izopet Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial J Hepatol 35 2001 272 278
52. N. Afdhal, R. Levine, and M. Black Colchicine versus PEG-Intron longterm: 1 year data from the COPILOT study (abstr) Gastroenterology 122 2002 P-218A
53. N. Afdhal, B. Freilich, R. Levine, M. Black, R. Brown, and H. Monsour Colchicine versus peg-intron long-term (COPILOT) trial: interim analysis of clinical outcomes at year 2 Hepatology 40 2004 238A